TherapeuticsMD (TXMD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts TXMD Hot Sheet
Join SI Premium – FREE
TherapeuticsMD (NYSE: TXMD) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $5.91 million.
For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- FactSet acquires BCC Group to expand real-time market data platform
- Ennis (EBF) Misses Q2 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
